

Patent Selections:

The patents annotated in this section have been selected from various patent collections. They are recent patents categorized by therapeutic area/agent/target and therapeutic agents related to anti-infective drug discovery and are relevant to the articles published in this journal issue.

SEVERE ACUTE RESPIRATORY SYNDROME (SARS)

- Gillim-Ross, L., Taylor, J., Scholl, D.R., Wentworth, D.E., Jollick, J.D. Compositions and methods for detecting severe acute respiratory syndrome coronavirus **US20067129042 (2006)**.
- Kung, H.-F., He, M.-L., Zheng, B.-J., Guan, Y., Lin, M.C.-M., Peng, Y. Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference **US20067129223 (2006)**.
- Johnson, R.A., Attardo, G. Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression **US20067144912 (2006)**.
- Ye, X.M., Garofalo, A.W., Lawler, R.D., Fukuda, J.Y., Konradi, A.W., Holcomb, R., Rossiter, K.I., Wone, D.W.G., Wu, J. Novel compounds useful for bradykinin B1 receptor antagonism **WO06113140 (2006)**.
- Penninger, J., Imai, Y., Kuba, K., Jiang, C. Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries **WO06122819 (2006)**.
- Jung, Y.-H., Choi, M.-K. Powder kimchi containing kimchi lactic acid bacteria **WO06123866 (2006)**.
- Paoletti, E., Tartaglia, J., Taylor, J., Gettig, R. Pox-virus-rabies recombinants and compositions and methods employing the recombinants **US20067144578 (2006)**.
- Cornett, G., Page, J., Page, K. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension **WO06128035 (2006)**.
- Scheuring, U., Bernard, I., Scheuring, U., Bernard, I. Combination therapy comprising a diaryl urea compound and a PI3, AKT kinase or MTOR inhibitors (Rapamycins) for cancer treatment **WO06125540 (2006)**.
- Guerciolini, R., Mcswiggen, J., Jadhav, V., Vargeese, C. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (SINA) **WO06128141 (2006)**.
- Shen, S., Hong, W., Lim, S.G., Tan, Y.J., Fielding, B.C., Goh, P.Y., Tan, T., Fu, J.L., SARS coronavirus S proteins and uses thereof **EP1701977 (2006)**.
- Bell, D., Mueller, S., Matthews, K. Novel hemoglobin scavenger receptor, CD163, and method of increasing CD163 expression on human stem cells and stimulation of erythroid progenitors **WO06094402 (2006)**.
- Van Der Werf, S., Escriou, N., Crescenzo-Chaigne, B., Manuguerra, J.-C., Kunst, F., Callendret, B., Betton, J.-M., Lorin, V., Gerbaud, S., Burguiere, A.M., Azebi, S., Charneau, P., Tangy, F., Combredet, C., Delagneau, J.-F., Martin, M. Novel strain of SARS-associated coronavirus and applications thereof **EP1694829 (2006)**.
- Jiang, S., He, Y. Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus **WO06086561 (2006)**.
- Boulos, S., Knuckey, N.W., Meloni, B. Neuroprotective agents and methods of their use **WO06084333 (2006)**.
- Fujii, N., Yamamoto, N. Anti-coronavirus drug **EP1652525 (2006)**.
- Enjuanes, S.L., Almazan, F. Dr. Vaccine against severe acute respiratory syndrome causing coronavirus (SARS-CoV) **EP1632564 (2006)**.
- Perry, M., Springthorpe, B. Piperidines for the treatment of chemokine mediated diseases **WO06126948 (2006)**.
- Denison, M. Methods of detecting coronavirus infections **WO06076007 (2006)**.
- Li, Q., Cohen, J. Cellular receptor for varicella-zoster virus, methods of inhibiting spread of varicella-zoster and methods of increasing stability and infectivity of the virus **WO06128026 (2006)**.
- Hirschman, S. Methods of treating and preventing severe acute respiratory syndrome (SARS) with AVR118 **WO06091222 (2006)**.
- Beadenkopf, R.J. Immunogenic SARS domain **WO06085933 (2006)**.
- Boojamra, C.G., Lin, K.-Y., Mackman, R.L., Markevitch, D.Y., Petrakovsky, O.V., Ray, A.S., Zhang, L. Phosphonate analogs of HIV inhibitor compounds **WO06110157 (2006)**.
- Nash, R.J., Slingsby, J.H., Carroll, M.W., Antiviral drug combinations, **WO06077427 (2006)**.
- Umezawa, K., Suzuki, E. Macrophage activation inhibitor **EP1656936 (2006)**.
- Romesberg, F., Cirz, R., Patten, P.A. Compositions and methods for enhancing drug sensitivity and treating drug resistant infections and diseases **WO06108075 (2006)**.
- Cui, X. Viral inhibitors **WO06113429 (2006)**.

28. Buckheit, R.W. Jr. Plasma or serum fraction for treatment or prevention of abnormal cell proliferation **WO06116381 (2006)**.
29. Mayumi, T., Tsutsumi, Y., Nakagawa, S., Ohta, T. TNF antagonists and TNF inhibitors comprising the same as the active ingredient **EP1717246 (2006)**.
30. Jones, P., Pryde, D.C. 2-Amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as Hepatitis C **WO06117670 (2006)**.

HELICOBACTER PYLORI INFECTION

1. Aygen, S. A method for the diagnosis of *Helicobacter pylori* infection and diagnostic KIT for performing the method **EP1685850 (2006)**.
2. Pettersson, A. Gastric acid secretion inhibiting composition **EP1731141 (2006)**.
3. Lockwood, S.F., O'Malley, S., Watumull, D.G., Hix, L.M., Jackson, H., Nadolski, G., Structural carotenoid analogs for the inhibition and amelioration of disease **US20067145025 (2006)**.
4. Covacci, A., Bugnoli, M., Telford, J., Macchia, G., Rappuoli, R. *Helicobacter pylori* proteins useful for vaccines and diagnostics **US20067141244 (2006)**.
5. Yue, J., Liao, Z., Yang, S., Fan, C., Dong, L., Wu, Y. Diarylheptanoids, preparation and the use thereof **WO06105728 (2006)**.
6. Baroli, B. Compositions facilitating drug penetration and drug retention in skin, **WO06113227 (2006)**.
7. Ellis, J., Charreyre, C., Martinon, O.M. Porcine circovirus and *Helicobacter* combination vaccines and methods of use **WO06113372 (2006)**.
8. Sella-Tavor, O., Pollock, S., Cojocar, G.S., Novik, A., Bazak, L., Tsyarkin, E., Wallach, S., Sameah-Greenwald, S. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis **WO06131928 (2006)**.
9. Ellis, J. Krakowka, G., Eaton, K., Flores, J. Porcine *Helicobacter* infection **WO06091721 (2006)**.
10. Cunningham, P.R. Novel targets for the identification of antibiotics that are not susceptible to antibiotic resistance **WO06122277 (2006)**.
11. Stroeman, P. New antibiotic-sensitive lactic acid bacteria strains **WO06119780 (2006)**.
12. Rango, D., Linder, R. Novel preparation and administration form comprising an acid-labile active compound **EP1616562 (2006)**.
13. Hubschwerlen, C., Surivet, J.-P., Zumbunn, A.C. New bicyclic antibiotics **WO06032466 (2006)**.
14. Surivet, J.-P., Hubschwerlen, C., Zumbunn, A.C. New piperidine antibiotics **WO06038172 (2006)**.
15. Stroeman, P. New antibiotic-sensitive lactic acid bacteria strains **EP1724340 (2006)**.

16. Wu, Y.-J. Novel erythromycin derivatives **EP1642901 (2006)**.
17. Breton, G.L. Nucleic acid sequences relating to *Bacteroides fragilis* for diagnostics and therapeutics **US20067090973 (2006)**.
18. Beck, V., Horvath, K. Method for assisting in differential diagnosis and treatment of autistic syndromes **US20067091182 (2006)**.
19. Chen, J. Photodynamic treatment of targeted cells **US20067018395 (2006)**.
20. Hunter, M.G., Beckett, R.P., Clements, J.M., Whittaker, M., Davies, S.J., Pratt, L.M., Spavold, Z.M., Launchbury, S. Antibacterial agents **US20067148198 (2006)**.

CHAGAS DISEASE

1. Doronina, S.O., Mendelsohn, B.A. Auristatins having an aminobenzoic acid unit at the N terminus **WO06132670 (2006)**.
2. Tsukamoto, T., Grella, B., Majer, P. Indoles as NAALADase inhibitors **US20067148250 (2006)**.
3. Witchey-Lakshmanan, L., Ugwu, S., Sandweiss, V., Hardalo, C., Hare, R.S., Krishna, G., Wang, Z., Taglietti, M., Particulate-stabilized injectable pharmaceutical compositions of posaconazole **WO06130177 (2006)**.
4. Chu, K., Williams, L.T., Wong, J.G.P., Hestir, K., Collins, A.L.T., Lee, E. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use **WO06124013 (2006)**.
5. Golan, I., Melnik, L., Naor, D., Nedvetzki, S., Golan, I. Variant CD44 polypeptide, polynucleotides encoding same, antibodies directed there against and method of using same for diagnosing and treating inflammatory diseases **EP1724286 (2006)**.
6. Minoprio, P., Alzari, P., Buschiazzo, A., Degrave, W., Gregoire, C., Chamond, N., Berneman, A. Crystallographic structure of trypanosoma cruzi proline racemase (TcPRACA) and uses thereof **EP1629092 (2006)**.
7. Burke, D., Switzer, W., Heneine, W., Folks, T., Wolfe, N., Eitel, M. Novel primate T-lymphotropic viruses **WO06091511 (2006)**.

CYTOMEGALOVIRUS DISEASE

1. Glick, G.D. Compositions relating to novel compounds and targets thereof **US20067144880 (2006)**.
2. Harley, J.B., James, J.A., Kaufman, K.M. Assays and therapies for latent viral infection **US20067078173 (2006)**.
3. Compton, T., Gellman, S.H., English, E.P., Chumanov, R.S. Beta-polypeptides that inhibit cytomegalovirus infection **WO06099170 (2006)**.
4. Coen, D.M., Loregian, A. Antiviral methods and compositions **WO06019955 (2006)**.

5. Tedder, T.F. Anti-CD19 antibody therapy for the transplantation **WO06133450 (2006)**.
6. Wood, C., Habib, N. Methylene blue therapy of viral disease **WO06127482 (2006)**.
7. Zeligs, M.A. Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus associated disease **WO06047716 (2006)**.
8. Iida, A., Ban, H., Inoue, M., Hirata, T., Hasegawa, M. Methods for producing minus-strand RNA viral vectors using hybrid promoter comprising cytomegalovirus enhancer and chicken beta-actin promoter **EP1717317 (2006)**.
9. Diamond, D.J. Immuno-reactive peptide CTL epitopes of human cytomegalovirus **EP1612217 (2006)**.
10. Khanna, R. Human cytomegalovirus immunotherapy **WO06056027 (2006)**.
11. Kemble, G.W., Greenberg, H. Duke, G. Recombinant human cytomegalovirus and vaccines comprising heterologous antigens **WO06004661 (2006)**.

LINEZOLID IN CHILDREN

1. Chaudhary, M. Treatment and control of severe infections including cystic fibrosis **WO06120705 (2006)**.
2. Buckheit, R.W. Jr. Plasma or serum fraction for the treatment or prevention of bacterial infections **WO06116380 (2006)**.
3. Osbakken, R.S., Hale, M.A., Leivo, F.T., Munk, J.D. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis **US20067128897 (2006)**.
4. Lane, E.M. Method and compositions for transdermal administration of antimicrobial medications **WO06104763 (2006)**.
5. Ramaty, R., Nidam, T., Braude, V., Adler, M. Isolated bis-linezolid, preparation thereof, and its use as a reference standard **WO06091848 (2006)**.
6. De Souza, N.J., Patel, M.V., Gupte, S.V., Upadhyay, D.J., Shukla, M.C., Chaturvedi, N.C., Bhawsar, S.B., Nair, S.C., Jafri, M.A., Khorakiwala, H.F. Inhibitors of cellular efflux pumps of microbes **US20067098219 (2006)**.

DRUG ABUSE AND DEPENDENCE

1. Ceci, A. Method for the treatment of drug abuse **WO06119884 (2006)**.

2. Dimpfel, W. Hesperidin for the treatment of epilepsy, migraine, schizoprenia, depression and drug abuse **EP1721613 (2006)**.
3. Rosenzweig-Lipson, S. Treatment of drug abuse **WO06116148 (2006)**.
4. La Pera, G. Use of inhibitors of steroid (testosterone) activity (i.e. estrogens) or antiandrogens) for treatment of substance correlated disorders like drug abuse **WO06097970 (2006)**.
5. Sabnani, S., Wesson, D., Dunn, J. Methods for the treatment of substance abuse and dependence **WO06110557 (2006)**.
6. Sanchez, M. Novel pharmaceutical compositions and the uses thereof for controlling the different forms of addiction to drugs **WO06048560 (2006)**.
7. Sabnani, S. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence **WO06110642 (2006)**.
8. Mueller, A.L., Moe, S.T. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases **US20067087765 (2006)**.
9. Boer, F.P., Kupper, R. Analogs and prodrugs of buprenorphine **US20067084150 (2006)**.
10. Woolhandler, R.A. Method of treating opioid dependency **WO06058029 (2006)**.
11. Bartlett, S. The use delta opioid receptor agonists and/or inverse agonists to inhibit the consumption of substances of abuse **WO06130471 (2006)**.
12. Mickle, T., Krishnan, S., Bishop, B., Lauderback, C., Moncrief, J.S., Oberlender, R., Piccariello, T. Abuse-resistant amphetamine compounds **US20067105486 (2006)**.
13. Cormier, M.J.N., Padmanabhan, R.V. Transdermal electrotransport drug delivery systems with reduced abuse potential **WO06091774 (2006)**.
14. Bristow, L., Fong, T.M., Morse, A.C. Methods for the treatment of substance abuse and addiction **WO06041769 (2006)**.